Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 80 for:    "Cervix Disease" | "Vaccines"

Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03935204
Recruitment Status : Not yet recruiting
First Posted : May 2, 2019
Last Update Posted : May 2, 2019
Sponsor:
Collaborators:
Xiamen Innovax Biotech Co., Ltd
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Information provided by (Responsible Party):
Jun Zhang, Xiamen University

Brief Summary:
This phase II clinical study was designed to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli)(hereafter called HPV vaccine), manufactured by Xiamen Innovax Biotech CO., LTD., in healthy adults aged 18-45 years old.

Condition or disease Intervention/treatment Phase
Condylomata Acuminata Cervical Cancer Biological: HPV Vaccine,270μg/1.0ml Biological: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: An Randomized, Double-Blinded, Placebo Controlled Phase II Clinical Trial to Estimate Immunogenicity of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Adults Aged 18 to 45 Years
Estimated Study Start Date : May 13, 2019
Estimated Primary Completion Date : December 13, 2019
Estimated Study Completion Date : April 13, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: HPV Vaccine,270μg/1.0ml
Participants in this arm would receive 270μg/1.0ml HPV vaccines.
Biological: HPV Vaccine,270μg/1.0ml
HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.

Placebo Comparator: Placebo
Participants in this arm would receive 1.0ml aluminium adjuvant.
Biological: Placebo
Aluminium adjuvant (1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
Other Name: aluminium adjuvant




Primary Outcome Measures :
  1. Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations at Months 7 (type specific neutralizing antibody) [ Time Frame: month 7 ]
    To detect the anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific neutralizing antibody level on day 0 (before the 1st dose) and one month after dose 3


Secondary Outcome Measures :
  1. Solicited local adverse reactions [ Time Frame: During the 7-day (Day 0-6) period following each vaccination ]
    Solicited local adverse reactions occurred within 7 days after each vaccination;

  2. Solicited systematic adverse reactions [ Time Frame: During the 7-day (Day 0-6) period following each vaccination ]
    Solicited systematic adverse reactions occurred within 7 days after each vaccination;

  3. Unsolicited adverse events [ Time Frame: Within 30 days (Day 0-29) after any vaccination ]
    Unsolicited adverse reactions occurred within 30 days after each vaccination;

  4. Serious adverse events [ Time Frame: throughout the study period, an average of 7 months ]
    Serious adverse events occurred throughout the study;


Other Outcome Measures:
  1. Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations at Months 7 (type specific IgG antibody) [ Time Frame: month 7 ]
    To detect the anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific IgG antibody level on day 0 (before the 1st dose) and one month after dose 3

  2. Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations in a immunogenicity subgroup at Months 1,2 and 7 (type specific neutralizing antibody and IgG antibody) [ Time Frame: month 1,2 and 6 ]
    To detect the anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific neutralizing and IgG antibody level of a immunogenicity subgroup at month 1,2 and 6.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Health women aged between 18 and 45 years.
  2. Judged as healthy and eligible for vaccination by the investigators through a self-reported medical history and some physical examinations.
  3. Able to comply with the requests of the study.
  4. Written informed consent obtained from the participants.
  5. Axillary temperature not higher than 37.0°C
  6. Non-pregnant women verified by a urine pregnancy test.

Exclusion Criteria:

  1. Pregnant or breastfeeding or plan to be pregnant within 7 months.
  2. Use of any investigational product or non-registered product (drug or vaccine) within 30 days preceding the first dose of the study vaccine or plan to use during the study period.
  3. Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy for more than 14 days in the 6 months before entry, except local treatment.
  4. Administration of any immunoglobulin or blood products within 3 months preceding the first dose of the study vaccine or plan to use within 7 months.
  5. Administration of any attenuated live vaccines within 21 days preceding the first dose of the study vaccine or any subunit or inactivated vaccines within 14 days before vaccination.
  6. Had a fever (axillary temperature over 38°C) within 3 days or acute illness requiring systemic antibiotics or antiviral treatment within 5 days before vaccination.
  7. Having the plan to participate another clinical trial during the study period.
  8. Received another HPV vaccine.
  9. Immunodeficiency , primary disease of important organs, malignant tumor, or any immune disease (such as systemic lupus erythematosus, arthritis pauperum, splenectomy or functional asplenia or other disease which might affect immune response).
  10. History of allergic disease or history of serious adverse events occurring after vaccination, i.e., allergy, urticaria, dyspnea, angioneurotic edema or abdominal pain.
  11. Asthma that required emergent treatment, hospitalization, oral or intravenous corticosteroid for unstable condition within the past 2 years.
  12. Having serious disease of internal medicine, such as hypertension, cardiac disease, diabetes, hyperthyroidism et al.
  13. Diagnosed coagulant function abnormality or blood coagulation disorder.
  14. Epilepsy, except fever epilepsy at under 2 years of age, alcohol-induced epilepsy in 3 years before abstinence, or idiopathic epilepsy requiring no treatment in the past 3 years.
  15. Past or current two-stage affective psychosis, not well controlled in the past 2 years or requiring drugs, or hve a tendency to commit suicide in the past 5 years.
  16. Other medical, psychological, social or occupational factors that, according to the investigators' judgment, might affect the individual's ability to obey the protocol or sign the informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03935204


Contacts
Layout table for location contacts
Contact: Jun Zhang, Master 86-592-2184110 zhangj@xmu.edu.cn
Contact: Ting Wu, Ph.D. 86-592-2880621 wuting@xmu.edu.cn

Locations
Layout table for location information
China, Jiangsu
Jiangsu Provincial Centre for Disease Control and Prevention Not yet recruiting
Nanjing, Jiangsu, China, 210009
Contact: Yuemei Hu, Bachelor    86-25-83759399    huyuemei@hotmail.com   
Principal Investigator: Yuemei Hu, Bachelor         
Sponsors and Collaborators
Xiamen University
Xiamen Innovax Biotech Co., Ltd
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Investigators
Layout table for investigator information
Study Chair: Jun Zhang, Master Xiamen University
Principal Investigator: Yue-Mei Hu, Bachelor Jiangsu Provincial Centre for Disease Control and Prevention

Layout table for additonal information
Responsible Party: Jun Zhang, professor, Xiamen University
ClinicalTrials.gov Identifier: NCT03935204     History of Changes
Other Study ID Numbers: HPV-PRO-008
First Posted: May 2, 2019    Key Record Dates
Last Update Posted: May 2, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jun Zhang, Xiamen University:
human papillomavirus vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Diseases
Vaccines
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Genital Diseases, Female
Immunologic Factors
Physiological Effects of Drugs